Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

[1]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[2]  N. Sugimoto,et al.  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Ajani,et al.  Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. K. Baek,et al.  Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Ying Cheng,et al.  Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  David Moher,et al.  Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. , 2013, JAMA.

[7]  Corneel Coens,et al.  Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. , 2011, Journal of the National Cancer Institute.

[8]  A. Hinke,et al.  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). , 2011, European journal of cancer.

[9]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[10]  D. Cunningham,et al.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  C. V. D. Velde,et al.  Gastric cancer – Authors' reply , 2009, The Lancet.

[12]  Tae Won Kim,et al.  Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. , 2007, Japanese journal of clinical oncology.

[13]  D Feldman-Stewart,et al.  Communicating quality of life information to cancer patients: a study of six presentation formats. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Bottomley,et al.  Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. , 2004, European journal of cancer.

[15]  G. Colucci,et al.  Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). , 2003, Anticancer research.

[16]  D. Alderson,et al.  Feasibility of quality of life assessment in patients with upper gastrointestinal tract cancer , 2003, British Journal of Cancer.

[17]  K. Abrams,et al.  Simultaneous analysis of quality of life and survival data , 2002, Statistical methods in medical research.

[18]  M. Koller,et al.  Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. , 2001, European journal of cancer.

[19]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[20]  P. Fayers,et al.  Analysis of messy longitudinal data from a randomized clinical trial. MRC Lung Cancer Working Party. , 2000, Statistics in medicine.

[21]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[22]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[23]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[24]  D. Schoenfeld,et al.  Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. , 1982, Biometrics.

[25]  J. Fraser,et al.  TREATMENT OF EARLY BREAST CANCER , 1978, The Lancet.

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[27]  J. Thigpen.  Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone , 2012 .

[28]  S. Bhatia,et al.  Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  L. Assersohn,et al.  Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  H. Espejo,et al.  [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.

[31]  Andrew Bottomley,et al.  EORTC QLQ-C30 Scoring Manual , 1995 .

[32]  D. Cox.  Regression Models and Life-Tables , 1972 .